MONDAY, Feb. 27, 2017 (HealthDay News) — For women with low-grade serous carcinoma of the ovary or peritoneum, hormonal maintenance therapy (HMT) is associated with improved progression-free survival (PFS), according to a study published online Feb. 21 in the Journal of Clinical Oncology.
David M. Gershenson, M.D., from the University of Texas MD Anderson Center in Houston, and colleagues compared PFS and overall survival associated with HMT versus routine observation (OBS) after primary cytoreductive surgery and platinum-based chemotherapy for 203 women with stage II to IV low-grade serous carcinoma of the ovary or peritoneum. Overall, 133 patients underwent OBS and 70 received HMT.
The researchers found that the median PFS was 26.4 and 64.9 months for patients who underwent OBS and HMT, respectively (P < 0.001). Overall survival did not differ significantly between the two groups (102.7 versus 115.7 months, respectively; P = 0.42). The median PFS was superior for patients who received HMT for subgroups of women who were disease free (81.1 versus 30.0 months; P < 0.001) or had persistent disease (38.1 versus 15.2 months; P < 0.001). Compared with women who underwent OBS, those who received HMT had a significantly lower risk of disease progression (hazard ratio, 0.44; 95 percent confidence interval, 0.31 to 0.64; P < 0.001).
“Women with stage II to IV low-grade serous carcinoma who received HMT after primary treatment had significantly longer PFS compared with women who underwent OBS,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Copyright © 2017 HealthDay. All rights reserved.